POAI.OQ
Latest Trade
1.00USDChange
0.07(+7.69%)Volume
374,097Today's Range
-
1.0152 Week Range
-
5.30As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 0.93 |
|---|---|
Open | 0.93 |
Volume | 374,097 |
3M AVG Volume | 24.97 |
Today's High | 1.01 |
Today's Low | 0.91 |
52 Week High | 5.30 |
52 Week Low | 0.63 |
Shares Out (MIL) | 24.09 |
Market Cap (MIL) | 22.37 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Predictive Oncology Reports Third Quarter 2020 Financial Results, Provides Business Update
Predictive Oncology- On Oct 14, Co Received Letter From Nasdaq Informing Co Does Not Comply With Minimum Closing Bid Price Requirement
Predictive Oncology Reports Qtrly Loss Per Share $0.36
Predictive Oncology Inc. is focused on applying artificial intelligence (AI) to personalized medicine and drug discovery. It operates through its subsidiaries, Helomics Holding Corporation (Helomics), TumorGenesis Inc., Skyline Europe and Skyline Medical Inc. Helomics applies AI to its data gathered from patient tumors to both personalize cancer therapies for patients and focusses on the development of new-targeted therapies. Helomics’ clinical laboratory improvement amendments (CLIA)-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions. Its TumorGenesis Inc. is engaged in developing approach to tumors in the laboratory. Skyline Medical Inc. markets its STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions.
Industry
Medical Equipment & Supplies
Contact Info
2915 Commers Dr Ste 900
EAGAN, MN
55121-2363
United States
+1.651.3894800
http://www.precisiontherapeutics.comExecutive Leadership
Carl Schwartz
President, Chief Executive Officer, Director
Robert L Myers
Chief Financial Officer
David O. Johnson
Senior Vice President - Operations
J. Melville Engle
Director
H. Richard Gabriel
Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 17.13 |
Price To Book (MRQ) | 1.26 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 47.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -161.42 |
Return on Equity (TTM) | -98.06 |
* PREDICTIVE ONCOLOGY FILES PROSPECTUS RELATES TO OFFER, RESALE OF UP TO 1.7 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS Source text (https://bit.ly/2NFewwm) Further company coverage:
* PREDICTIVE ONCOLOGY INC FILES PRELIMINARY PROSPECTUS RELATED TO OFFER AND RESALE OF UP TO 3.3 MILLION SHARES OF COMMON STOCK - SEC FILING Source text for Eikon: https://bit.ly/2VeChQc Further company coverage:
* PREDICTIVE ONCOLOGY’S TUMORGENESIS DIVISION SECURES FIRST COMMERCIAL SALE OF ITS NOVEL OVARIAN CANCER CELL MEDIA Source text for Eikon: Further company coverage:
* PREDICTIVE ONCOLOGY INC FILES PROSPECTUS RELATES TO OFFER AND RESALE OF UP TO 1.7 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text - https://bit.ly/2BhvXAo Further company coverage:
* PREDICTIVE ONCOLOGY REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS, PROVIDES BUSINESS UPDATE
* PREDICTIVE ONCOLOGY (NASDAQ SYMBOL POAI) IS LICENSING AND PARTNERING THIS GROUNDBREAKING NSP10 TECHNOLOGY IN THE RACE TO DEVELOP A VACCINE FOR DEVELOPMENT Source text for Eikon: Further company coverage:
* PREDICTIVE ONCOLOGY ANNOUNCES $2.2 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
* PREDICTIVE ONCOLOGY INC FILES PROSPECTUS RELATES TO OFFER, RESALE OF UP TO 5.9 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS Source: https://bit.ly/2RiUERX Further company coverage:
* PREDICTIVE ONCOLOGY REPORTS 2019 FULL-YEAR FINANCIAL RESULTS
* PREDICTIVE ONCOLOGY INC - ON MARCH 19, ENTERED INTO A THIRD AMENDMENT TO AMENDED AND RESTATED SENIOR SECURED PROMISSORY NOTE DATED SEPTEMBER 28, 2018
* PREDICTIVE ONCOLOGY LAUNCHES NEW AI PLATFORM FOR VACCINE AND DRUG DEVELOPMENT TARGETING CORONAVIRUSES AND ACUTE RESPIRATORY SYNDROMES (COVID-19, MERS, AND SARS)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.